VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the Hong Kong Patents Registry Intellectual Property Department has granted a patent related to certain methods of production for AV-101, VistaGen’s oral NMDA (N-methyl-D-aspartate) receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder (MDD).

As quoted in the press release:

The new Hong Kong patent (No. 1218414) is the counterpart to previously issued  U.S. Patent No. 9,834,801, European Patent No. EP2970097, and Chinese Patent No. ZL201480023992.8 and will not expire until at least 2034.

Shawn Singh, Chief Executive Officer of VistaGen, stated, “Receiving this patent in Hong Kong, along with its counterpart patent in China, strengthens our commercial protection in two key markets in Asia and is another significant step forward in our global IP plan for AV-101.”

Click here to read the full press release.